Conjustar Biologics Awarded to PharmCube's "Top 15 Emerging Innovative Drug Enterprises in China – 2025"

Shanghai, China – May 21, 2026​ – Conjustar Biologics (星联肽生物), a clinical-stage biotech company focused on miniaturized conjugate drugs—peptide-drug conjugates (PDCs) and Nanobody-drug conjugates (NDCs)—has been awarded to PharmCube's "Top 15 Emerging Innovative Drug Enterprises in China (2025)"​ at the 2026 OneBD Pharmaceutical Investment & BD Conference, held May 21 in Shanghai.

The award is based on PharmCube's comprehensive evaluation using its industry database, quantitative models, and expert analysis, assessing Chinese innovative drug companies on R&D innovation, global partnership capability, and industrialization progress. Conjustar Biologics was recognized for its deep technical expertise in miniaturized conjugate drug platforms and sustained innovation in oncology.

This honor reflects both industry recognition of Conjustar's R&D capabilities and growing market anticipation for the clinical potential of miniaturized conjugate drugs in solid tumor treatment.